Jako respondentka byla předem definována osoba mající zvýšení počtu uspokojujících sexuálních aktivit > 1 v období 4 týdnů.
In the combined phase III data, excluding patients taking oral CEE, in whom there was no significant improvement in sexual function, 50.7% of women (n=274) treated with Intrinsa and 29.4% of those treated with placebo (n=269) were responders with regard to total satisfying sexual activity (primary endpoint), when a responder was predefined as having an increase in the 4-week frequency of satisfying activities of > 1.